As expected, prior targeted therapy, which was overwhelmingly EGFR-targeted, increased the proportion of cancers with BRAF V600E (12.6% vs. 6.5%, p = 0.019) and ERBB2 amplification (5.9% vs. 2.3%, p = 0.043). The gene discussed is BRAF; the disease is cancer.